Our Pipeline

Pushing the boundaries of breakthrough therapies

Ivonescimab (SMT112)
Summit is initiating development activities for SMT112 and will do so first in NSCLC indications.
Summit plans to start treating patients in clinical studies by the second quarter of 2023.

Summit Research
Focused on innovations leveraging deep leadership expertise in discovery and advancement of novel molecules, including ivonescimab.​

*Phase I and II has been completed by our partner Akeso, Phase III clinical studies are planned to be initiated either independently or jointly with our partner Akeso in 2023/24

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.
It is currently being investigated in Phase III clinical studies.